There are currently 1958 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
NCT02843945
Recruiting
Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Pancreatic Cancer
Register for Updates
RH Genotype Matched RBC Transfusions
NCT04156893
Recruiting
To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.
Gender:
All
Ages:
6 months and above
Trial Updated:
05/24/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Sickle Cells Disease
Register for Updates
Study of AZD0754 in Participants With Metastatic Prostate Cancer
NCT06267729
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
Gender:
Male
Ages:
Between 18 years and 130 years
Trial Updated:
05/24/2024
Locations: Research Site, Philadelphia, Pennsylvania
Conditions: Metastatic Prostate Cancer
Register for Updates
iHERO Study: Insurance, Health and Economic Resources Online for Emerging Adults With Type 1 Diabetes
NCT06348160
Recruiting
This research study aims to test a financial and health insurance iHERO Toolkit for young adults with type1 diabetes. The iHERO Toolkit was developed over one year with the type 1 diabetes community, The Diabetes Link organization, and experts. Now, the investigators want to understand the impact of the iHERO Toolkit on diabetes self-management, financial stress, and health insurance literacy outcomes. The investigators are doing this study because it will help to better understand how to suppor... Read More
Gender:
All
Ages:
Between 18 years and 30 years
Trial Updated:
05/24/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Type 1 Diabetes
Register for Updates
Pencil Beam Scanning in Patients With Renal Tumors
NCT03810651
Recruiting
This is a pilot study to assess acute toxicity in patients receiving flank irradiation using proton therapy for renal tumors.
Gender:
All
Ages:
Between 0 years and 30 years
Trial Updated:
05/24/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Renal Tumor, Wilms Tumor
Register for Updates
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
NCT06409130
Recruiting
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or "dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: University of Pennsylvania Hospital, Philadelphia, Pennsylvania
Conditions: Alcohol-related Liver Disease
Register for Updates
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
NCT06354660
Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Clinical Research of Philadelphia, Philadelphia, Pennsylvania
Conditions: Diabetes Type 2
Register for Updates
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
NCT04071847
Recruiting
The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling tremor and dystonia.
Gender:
All
Ages:
All
Trial Updated:
05/24/2024
Locations: Thomas Jefferson Department or Neurosurgery, Philadelphia, Pennsylvania
Conditions: Movement Disorders, Parkinson Disease, Essential Tremor, Tremor, Dystonia, Primary Dystonia, Secondary Dystonia
Register for Updates
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NCT05999994
Recruiting
The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.
Gender:
All
Ages:
Between 1 year and 39 years
Trial Updated:
05/23/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Neoplasms, Child, Adolescent
Register for Updates
A Study to Evaluate Safety, Efficacy of FF-10832 in Combination With Pembrolizumab in Solid Tumors
NCT05318573
Recruiting
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Hospital of the Univ of Pennsylvania Perlman Center, Philadelphia, Pennsylvania
Conditions: Advanced Solid Tumor
Register for Updates
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
NCT04562766
Recruiting
This is a randomized, double-blind study of rilzabrutinib in participants with persistent or chronic ITP, with an average platelet count of <30,000/μL (and no single platelet count >35,000/μL) on two counts at least 5 days apart in the 14 days before treatment begins. Participants will receive rilzabrutinib or placebo 400mg twice daily. For each participant, the study will last up to 60 weeks from the start of the Screening Period to the End of Study (EOS) visit. This includes Screening (up to... Read More
Gender:
All
Ages:
10 years and above
Trial Updated:
05/23/2024
Locations: The Children's Hospital of Philadelphia (CHOP)_Investigational Site Number 84027, Philadelphia, Pennsylvania
Conditions: Immune Thrombocytopenia
Register for Updates
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
NCT04104672
Recruiting
This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with Zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania +1 locations
Conditions: Advanced Pancreatic Cancer
Register for Updates